Trial Profile
Efficacy and safety of apatinib mesylate in the treatment of recurrent uterine malignancies with failure of second-line and above chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Uterine cancer
- Focus Therapeutic Use
- 25 Oct 2018 New trial record